AU2002952492A0 - Chaperonin 10 immunosuppression - Google Patents

Chaperonin 10 immunosuppression

Info

Publication number
AU2002952492A0
AU2002952492A0 AU2002952492A AU2002952492A AU2002952492A0 AU 2002952492 A0 AU2002952492 A0 AU 2002952492A0 AU 2002952492 A AU2002952492 A AU 2002952492A AU 2002952492 A AU2002952492 A AU 2002952492A AU 2002952492 A0 AU2002952492 A0 AU 2002952492A0
Authority
AU
Australia
Prior art keywords
donor
recipient animal
cpn10
administration
host disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002952492A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CBio Ltd
Original Assignee
CBio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CBio Ltd filed Critical CBio Ltd
Priority to AU2002952492A priority Critical patent/AU2002952492A0/en
Publication of AU2002952492A0 publication Critical patent/AU2002952492A0/en
Priority to EP10174226.0A priority patent/EP2255824B1/en
Priority to KR1020057008096A priority patent/KR101088740B1/ko
Priority to EP03769073A priority patent/EP1569679B1/en
Priority to AU2003277992A priority patent/AU2003277992B2/en
Priority to DK03769073.2T priority patent/DK1569679T3/da
Priority to US10/534,193 priority patent/US7618935B2/en
Priority to EP14177983.5A priority patent/EP2818179A1/en
Priority to PT03769073T priority patent/PT1569679E/pt
Priority to JP2004548934A priority patent/JP4716731B2/ja
Priority to ES03769073T priority patent/ES2351993T3/es
Priority to CNB2003801082969A priority patent/CN100525832C/zh
Priority to DE60335202T priority patent/DE60335202D1/de
Priority to NZ540433A priority patent/NZ540433A/en
Priority to SI200331912T priority patent/SI1569679T1/sl
Priority to PCT/AU2003/001467 priority patent/WO2004041300A1/en
Priority to AT03769073T priority patent/ATE489963T1/de
Priority to CA2505141A priority patent/CA2505141C/en
Priority to US12/572,195 priority patent/US8067361B2/en
Priority to CY20101101115T priority patent/CY1110972T1/el
Priority to JP2010286005A priority patent/JP2011088920A/ja
Priority to US13/290,996 priority patent/US20120082690A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Glass Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2002952492A 2002-11-06 2002-11-06 Chaperonin 10 immunosuppression Abandoned AU2002952492A0 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
AU2002952492A AU2002952492A0 (en) 2002-11-06 2002-11-06 Chaperonin 10 immunosuppression
CA2505141A CA2505141C (en) 2002-11-06 2003-11-06 Chaperonin 10 immunosuppression
ES03769073T ES2351993T3 (es) 2002-11-06 2003-11-06 Inmunosupresión mediante chaperonina 10.
DE60335202T DE60335202D1 (en) 2002-11-06 2003-11-06 Chaperonin-10-immunosuppression
EP03769073A EP1569679B1 (en) 2002-11-06 2003-11-06 Chaperonin 10 immunosuppression
AU2003277992A AU2003277992B2 (en) 2002-11-06 2003-11-06 Chaperonin 10 immunosuppression
DK03769073.2T DK1569679T3 (da) 2002-11-06 2003-11-06 Chaperonin-10-immunosuppression
US10/534,193 US7618935B2 (en) 2002-11-06 2003-11-06 Chaperonin 10 immunosuppression
EP14177983.5A EP2818179A1 (en) 2002-11-06 2003-11-06 Chaperonin 10 immunosuppression
PT03769073T PT1569679E (pt) 2002-11-06 2003-11-06 Imunossupressão com chaperonina 10
JP2004548934A JP4716731B2 (ja) 2002-11-06 2003-11-06 シャペロニン１０免疫抑制
EP10174226.0A EP2255824B1 (en) 2002-11-06 2003-11-06 Chaperonin 10 for use in treatment of graft versus host disease (GVHD) alone or in combination with another immunosuppressive agent or a steroid
CNB2003801082969A CN100525832C (zh) 2002-11-06 2003-11-06 伴侣蛋白10的免疫抑制作用
KR1020057008096A KR101088740B1 (ko) 2002-11-06 2003-11-06 샤페로닌 10을 이용한 면역억제 방법
NZ540433A NZ540433A (en) 2002-11-06 2003-11-06 Treatment and management graft versus host disease (GVHD) by administering chaperonin 10 (cpn10) to a recipient animal
SI200331912T SI1569679T1 (sl) 2002-11-06 2003-11-06 Imunosupresija s šaperoninom 10
PCT/AU2003/001467 WO2004041300A1 (en) 2002-11-06 2003-11-06 Chaperonin 10 immunosuppression
AT03769073T ATE489963T1 (de) 2002-11-06 2003-11-06 Chaperonin-10-immunosuppression
US12/572,195 US8067361B2 (en) 2002-11-06 2009-10-01 Chaperonin 10 immunosuppression
CY20101101115T CY1110972T1 (el) 2002-11-06 2010-12-03 Ανοσοκαταστολη με σαπερονινη 10
JP2010286005A JP2011088920A (ja) 2002-11-06 2010-12-22 シャペロニン１０免疫抑制
US13/290,996 US20120082690A1 (en) 2002-11-06 2011-11-07 Chaperonin 10 immunosuppression

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2002952492A AU2002952492A0 (en) 2002-11-06 2002-11-06 Chaperonin 10 immunosuppression

Publications (1)

Publication Number Publication Date
AU2002952492A0 true AU2002952492A0 (en) 2002-11-21

Family

ID=28795882

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002952492A Abandoned AU2002952492A0 (en) 2002-11-06 2002-11-06 Chaperonin 10 immunosuppression

Country Status (16)

Country Link
US (3) US7618935B2 (https=)
EP (3) EP2255824B1 (https=)
JP (2) JP4716731B2 (https=)
KR (1) KR101088740B1 (https=)
CN (1) CN100525832C (https=)
AT (1) ATE489963T1 (https=)
AU (1) AU2002952492A0 (https=)
CA (1) CA2505141C (https=)
CY (1) CY1110972T1 (https=)
DE (1) DE60335202D1 (https=)
DK (1) DK1569679T3 (https=)
ES (1) ES2351993T3 (https=)
NZ (1) NZ540433A (https=)
PT (1) PT1569679E (https=)
SI (1) SI1569679T1 (https=)
WO (1) WO2004041300A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005204979B2 (en) * 2004-01-16 2010-10-21 Cbio Limited Chaperonin 10 modulation of toll-like receptor-inducible cytokine and chemokine secretion
NZ548985A (en) * 2004-01-16 2010-02-26 Cbio Ltd Chaperonin 10 modulation of toll-like receptor-inducible cytokine and chemokine secretion
US8036710B2 (en) * 2004-05-07 2011-10-11 Qualcomm, Incorporated Power-efficient multi-antenna wireless device
AU2006269824B2 (en) * 2005-07-11 2012-04-19 Cbio Limited Chaperonin 10-induced immunomodulation
BRPI0613515A2 (pt) * 2005-07-11 2011-01-11 Cbio Ltd imunomodulação induzida por chaperonina 10
EP2457930A1 (en) * 2005-08-31 2012-05-30 CBIO Limited Modified chaperonin 10
AU2006303826B2 (en) * 2005-10-20 2012-07-19 Cbio Limited Treatment of hypersensitivity
CN101330922A (zh) * 2005-10-20 2008-12-24 悉生物有限公司 超敏的治疗
CA2644058C (en) 2006-03-02 2016-08-09 Cbio Limited Regulation of immune responses by modulation of the function of antigen presenting cells
CA2720617A1 (en) * 2008-04-11 2009-10-15 Cbio Limited Modified cpn10 and prr signalling
US20110243921A1 (en) * 2010-03-30 2011-10-06 Cbio Limited Prevention and treatment of cutaneous lupus erythematosus
WO2013158959A1 (en) * 2012-04-19 2013-10-24 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of graft-versus-host disease
WO2014063194A1 (en) 2012-10-23 2014-05-01 The University Of Sydney Elastic hydrogel
BR112015013627A2 (pt) 2012-12-10 2017-07-11 Elastagen Pty Ltd elástico escalável tridimensional, fabricação e construção
JP6382311B2 (ja) 2013-08-13 2018-08-29 エラスタジェン・プロプライエタリー・リミテッドＥｌａｓｔａｇｅｎ Ｐｔｙ Ｌｔｄ 損傷組織の再生

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2176948C (en) * 1993-11-30 2007-05-15 Halle Morton Chaperonin 10
WO1995015339A1 (en) * 1993-11-30 1995-06-08 The University Of Queensland Antagonists to chaperonin 10
US5989804A (en) * 1994-07-08 1999-11-23 New England Medical Center Hospitals, Inc. E6 binding proteins
JPH11510806A (ja) * 1995-08-09 1999-09-21 シェーリング コーポレイション 免疫抑制治療のためのインターロイキン１０およびシクロスポリンの併用
US20020142000A1 (en) * 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
CA2383213A1 (en) * 1999-09-10 2001-03-15 Fordham University Methods and compositions for the treatment and prevention of graft rejection using heat shock proteins
GB0028122D0 (en) * 2000-11-17 2001-01-03 St Georges Entpr Ltd Method

Also Published As

Publication number Publication date
JP2006508099A (ja) 2006-03-09
CA2505141A1 (en) 2004-05-21
DK1569679T3 (da) 2011-01-10
US8067361B2 (en) 2011-11-29
NZ540433A (en) 2008-03-28
ES2351993T3 (es) 2011-02-14
PT1569679E (pt) 2010-12-14
CA2505141C (en) 2012-07-17
US20120082690A1 (en) 2012-04-05
JP2011088920A (ja) 2011-05-06
CN100525832C (zh) 2009-08-12
EP2818179A1 (en) 2014-12-31
US7618935B2 (en) 2009-11-17
EP2255824B1 (en) 2014-07-23
ATE489963T1 (de) 2010-12-15
US20060198834A1 (en) 2006-09-07
JP4716731B2 (ja) 2011-07-06
CY1110972T1 (el) 2015-06-11
WO2004041300A1 (en) 2004-05-21
EP1569679B1 (en) 2010-12-01
US20100099605A1 (en) 2010-04-22
EP2255824A1 (en) 2010-12-01
SI1569679T1 (sl) 2011-01-31
KR20050086428A (ko) 2005-08-30
KR101088740B1 (ko) 2011-12-01
CN1735428A (zh) 2006-02-15
DE60335202D1 (en) 2011-01-13
EP1569679A4 (en) 2008-02-27
EP1569679A1 (en) 2005-09-07

Similar Documents

Publication Publication Date Title
CY1110972T1 (el) Ανοσοκαταστολη με σαπερονινη 10
WO2004028243A3 (en) Porcine animals lacking any expression of functional alpha 1,3 galactosyltransferase
WO1999062425A3 (en) Bioengineered vascular graft prostheses
BR0203650A (pt) Estentor de auto-articulação
EP1688425A3 (en) Cyclic salen-metal compounds as scavengers for oxygen radicals and useful as antioxidants in the treatment and prevention of diseases
MXPA03005893A (es) Proteccion, restauracion, y mejora de celulas, tejidos y organos que responden a la eritropoyetina.
ZA914456B (en) Treatment of organ transplantation rejection
SI1546088T1 (sl) Spojine za uporabo v zdravljenju avtoimunskih bolezni, imunoalergijskih bolezni in zavrnitve transpalantata organa ali tkiva
WO1999004772A3 (en) Use of levobupivacaine
EP1676574A3 (en) Methods for promoting survival of transplanted tissues and cells
BR9612821A (pt) Métodos para a prevenção de rejeição de enxerto em transplante e para a produção de uma célula de hospedeiro para terapia genética universal
AU2003222513A1 (en) Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure
SI1567171T1 (sl) Uporaba dekstran sulfata za zdravljenje IBMIR
WO2001068828A3 (en) Compositions and methods for regulated protein expression in gut
HU901516D0 (en) The use of s-adenosile-methionine in the treatment of pancreatitis, and in preventing the natural rejection of transplanted pancreas
WO2004091436A3 (en) Methods and compositions for treating ocular disease
DE3875306D1 (de) Immunosuppression bei der auf immunotoxin basierten behandlung von menschen.
WO2005058280A3 (en) Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
EP1964572A3 (en) Compositions and methods for protecting organs, tissue and cells from immune system-mediated damage
CA2283450A1 (en) Methods for treatment of scar tissue
AU4747497A (en) Sordarin derivatives
WO2004037167A3 (en) Methods of treating dry eye disease with lantibiotics
PL338678A1 (en) Derivatives of 4-cyano-4-deformylsordacin
WO2001045680A3 (en) Cd45 inhibitors
ATE188485T1 (de) Neuer peptidischer wirkstoff und dessen herstellung